<?xml version='1.0' encoding='utf-8'?>
<document id="21128991"><sentence text="Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects."><entity charOffset="64-73" id="DDI-PubMed.21128991.s1.e0" text="ritonavir" /><entity charOffset="146-156" id="DDI-PubMed.21128991.s1.e1" text="lamivudine" /><entity charOffset="157-167" id="DDI-PubMed.21128991.s1.e2" text="zidovudine" /><pair ddi="false" e1="DDI-PubMed.21128991.s1.e0" e2="DDI-PubMed.21128991.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21128991.s1.e0" e2="DDI-PubMed.21128991.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21128991.s1.e0" e2="DDI-PubMed.21128991.s1.e2" /><pair ddi="false" e1="DDI-PubMed.21128991.s1.e1" e2="DDI-PubMed.21128991.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21128991.s1.e1" e2="DDI-PubMed.21128991.s1.e2" /></sentence><sentence text="BILR 355 is a second generation non-nucleoside reverse transcriptase inhibitor" /><sentence text=" It has shown promising in vitro anti-HIV-1 activities and favourable human pharmacokinetic properties after co-administration with ritonavir (RTV)"><entity charOffset="132-141" id="DDI-PubMed.21128991.s3.e0" text="ritonavir" /><entity charOffset="143-146" id="DDI-PubMed.21128991.s3.e1" text="RTV" /><pair ddi="false" e1="DDI-PubMed.21128991.s3.e0" e2="DDI-PubMed.21128991.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21128991.s3.e0" e2="DDI-PubMed.21128991.s3.e1" /></sentence><sentence text=" Lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor"><entity charOffset="1-11" id="DDI-PubMed.21128991.s4.e0" text="Lamivudine" /><entity charOffset="13-16" id="DDI-PubMed.21128991.s4.e1" text="3TC" /><pair ddi="false" e1="DDI-PubMed.21128991.s4.e0" e2="DDI-PubMed.21128991.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21128991.s4.e0" e2="DDI-PubMed.21128991.s4.e1" /></sentence><sentence text=" It is excreted predominantly in urine by a transporter-mediated pathway" /><sentence text=" These two drugs are likely to be given together to HIV-infected patients" /><sentence text=" The objective of this study was to investigate any steady-state pharmacokinetic interactions between RTV-boosted BILR 355 and 3TC/zidovudine (ZDV)"><entity charOffset="127-130" id="DDI-PubMed.21128991.s7.e0" text="3TC" /><entity charOffset="131-141" id="DDI-PubMed.21128991.s7.e1" text="zidovudine" /><entity charOffset="102-111" id="DDI-PubMed.21128991.s7.e2" text="RTV" /><pair ddi="false" e1="DDI-PubMed.21128991.s7.e2" e2="DDI-PubMed.21128991.s7.e2" /><pair ddi="false" e1="DDI-PubMed.21128991.s7.e2" e2="DDI-PubMed.21128991.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21128991.s7.e2" e2="DDI-PubMed.21128991.s7.e1" /><pair ddi="false" e1="DDI-PubMed.21128991.s7.e0" e2="DDI-PubMed.21128991.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21128991.s7.e0" e2="DDI-PubMed.21128991.s7.e1" /></sentence><sentence text="" /><sentence text="This was a randomized, open label, prospective study" /><sentence text=" In group A, 39 healthy subjects were given 3TC/ZDV (150 mg/300 mg) twice daily (b"><entity charOffset="44-46" id="DDI-PubMed.21128991.s10.e0" text="3TC" /></sentence><sentence text="i" /><sentence text="d" /><sentence text=") for 7 days, and then BILR 355 and RTV (BILR 355/r, 150 mg/100 mg) were co-administered with this regimen for an additional 7 days"><entity charOffset="36-38" id="DDI-PubMed.21128991.s13.e0" text="RTV" /></sentence><sentence text=" Intensive blood samples were taken on days 7 and 14 for pharmacokinetic assessments" /><sentence text=" In group B, 12 healthy subjects were given BILR 355/r (150 mg/100 mg) b" /><sentence text="i" /><sentence text="d" /><sentence text=" for 7 days" /><sentence text=" The pharmacokinetic data from group B were pooled with data from group B subjects in other similar studies performed in parallel (BILR 355 alone group in BILR 355 drug-drug interaction studies with tipranavir, lopinavir/RTV, and emtricitabine/tenofovir DF; BILR 355 regimen was the same)"><entity charOffset="199-209" id="DDI-PubMed.21128991.s19.e0" text="tipranavir" /><entity charOffset="211-220" id="DDI-PubMed.21128991.s19.e1" text="lopinavir" /><entity charOffset="230-243" id="DDI-PubMed.21128991.s19.e2" text="emtricitabine" /><entity charOffset="244-253" id="DDI-PubMed.21128991.s19.e3" text="tenofovir" /><entity charOffset="221-229" id="DDI-PubMed.21128991.s19.e4" text="RTV" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e0" e2="DDI-PubMed.21128991.s19.e0" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e0" e2="DDI-PubMed.21128991.s19.e1" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e0" e2="DDI-PubMed.21128991.s19.e4" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e0" e2="DDI-PubMed.21128991.s19.e2" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e0" e2="DDI-PubMed.21128991.s19.e3" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e1" e2="DDI-PubMed.21128991.s19.e1" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e1" e2="DDI-PubMed.21128991.s19.e4" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e1" e2="DDI-PubMed.21128991.s19.e2" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e1" e2="DDI-PubMed.21128991.s19.e3" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e4" e2="DDI-PubMed.21128991.s19.e4" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e4" e2="DDI-PubMed.21128991.s19.e2" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e4" e2="DDI-PubMed.21128991.s19.e3" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e2" e2="DDI-PubMed.21128991.s19.e2" /><pair ddi="false" e1="DDI-PubMed.21128991.s19.e2" e2="DDI-PubMed.21128991.s19.e3" /></sentence><sentence text="" /><sentence text="After co-administration with BILR 355/r, the AUC(12,ss) and C(max,ss) of 3TC increased by 45% and 24%, respectively; the elimination half-life (t(1/2) ,ss) of 3TC was significantly increased"><entity charOffset="73-75" id="DDI-PubMed.21128991.s21.e0" text="3TC" /><entity charOffset="159-161" id="DDI-PubMed.21128991.s21.e1" text="3TC" /><pair ddi="false" e1="DDI-PubMed.21128991.s21.e0" e2="DDI-PubMed.21128991.s21.e0" /><pair ddi="false" e1="DDI-PubMed.21128991.s21.e0" e2="DDI-PubMed.21128991.s21.e1" /></sentence><sentence text=" However, the pharmacokinetics of ZDV was unchanged" /><sentence text=" Co-administration with 3TC/ZDV resulted in a 22% decrease in AUC(12,ss) and a 20% decrease in C(max,ss) for BILR 355"><entity charOffset="24-26" id="DDI-PubMed.21128991.s23.e0" text="3TC" /></sentence><sentence text=" The observed increase in exposure and prolongation of t(1/2,ss) of 3TC is potentially related to inhibition of OCT-mediated urinary excretion of 3TC"><entity charOffset="68-70" id="DDI-PubMed.21128991.s24.e0" text="3TC" /><entity charOffset="146-148" id="DDI-PubMed.21128991.s24.e1" text="3TC" /><pair ddi="false" e1="DDI-PubMed.21128991.s24.e0" e2="DDI-PubMed.21128991.s24.e0" /><pair ddi="false" e1="DDI-PubMed.21128991.s24.e0" e2="DDI-PubMed.21128991.s24.e1" /></sentence><sentence text="" /><sentence text="Concomitant administration of BILR 355 with 3TC/ZDV resulted in a modest decrease in exposure to BILR 355 and a 45% increase in exposure to 3TC"><entity charOffset="44-46" id="DDI-PubMed.21128991.s26.e0" text="3TC" /><entity charOffset="140-142" id="DDI-PubMed.21128991.s26.e1" text="3TC" /><pair ddi="false" e1="DDI-PubMed.21128991.s26.e0" e2="DDI-PubMed.21128991.s26.e0" /><pair ddi="false" e1="DDI-PubMed.21128991.s26.e0" e2="DDI-PubMed.21128991.s26.e1" /></sentence><sentence text="" /></document>